ADAP - Adaptimmune Therapeutics Plc Stock Price, Fair Value and News

1.11USD-0.09 (-7.50%)Delayed

Market Summary

USD1.11-0.09

Delayed

-7.50%

ADAP Stock Price

View Fullscreen

ADAP RSI Chart

ADAP Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-10.42

Price/Sales (Trailing)

92.71

EV/EBITDA

-10.21

Price/Free Cashflow

-12.34

ADAP Price/Sales (Trailing)

ADAP Profitability

EBT Margin

-883.39%

Return on Equity

-670.4%

Return on Assets

-63.33%

Free Cashflow Yield

-8.11%

ADAP Fundamentals

ADAP Revenue

Revenue (TTM)

18.4M

Rev. Growth (Yr)

-88.07%

Rev. Growth (Qtr)

2.4K%

ADAP Earnings

Earnings (TTM)

-163.4M

Earnings Growth (Yr)

-4.8K%

Earnings Growth (Qtr)

-1.22%

Breaking Down ADAP Revenue

Last 7 days

-0.9%

Last 30 days

12.1%

Last 90 days

-7.5%

Trailing 12 Months

-15.3%

How does ADAP drawdown profile look like?

ADAP Financial Health

Current Ratio

2.81

ADAP Investor Care

Shares Dilution (1Y)

54.23%

Diluted EPS (TTM)

-0.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	18.4M	0	0	0
2023	71.2M	70.8M	71.1M	60.3M
2022	9.3M	11.7M	17.5M	27.1M
2021	3.6M	6.2M	6.2M	6.1M
2020	1.7M	2.2M	3.2M	4.0M
2019	0	40.0M	20.6M	1.1M
2018	43.2M	48.7M	62.3M	59.5M
2017	14.1M	17.3M	42.1M	37.8M
2016	14.7M	12.2M	9.7M	14.2M
2015	5.3M	9.9M	12.2M	14.5M
2014	0	825.0K	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Adaptimmune Therapeutics Plc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 17, 2024	rawcliffe adrian	sold	-20,243	0.673	-30,080	chief executive officer
Jan 17, 2024	bertrand william c jr	sold	-12,725	0.673	-18,908	chief operating officer
Jan 17, 2024	norry elliot	sold	-12,299	0.673	-18,276	chief medical officer
Jan 17, 2024	lunger john	sold	-12,190	0.673	-18,114	chief patient supply officer
Jan 16, 2024	norry elliot	sold	-1,806	0.79	-2,287	chief medical officer
Jan 16, 2024	rawcliffe adrian	sold	-7,350	0.79	-9,304	chief executive officer
Jan 16, 2024	bertrand william c jr	sold	-3,697	0.79	-4,681	chief operating officer
Jan 16, 2024	lunger john	sold	-3,697	0.79	-4,681	chief patient supply officer
Jan 12, 2024	norry elliot	sold	-6,661	0.8541	-7,799	chief medical officer
Jan 12, 2024	bertrand william c jr	sold	-4,458	0.8541	-5,220	chief operating officer

Which funds bought or sold ADAP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-77,381	-	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	401,340	401,340	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-92.83	-2,310,780	385,032	-%
May 15, 2024	BAKER BROS. ADVISORS LP	reduced	-1.66	8,344,850	17,043,500	0.21%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	573	157,277	169,948	-%
May 15, 2024	Royal Bank of Canada	added	18.24	1,000	1,000	-%
May 15, 2024	CSS LLC/IL	unchanged	-	24,162	48,509	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	new	-	22,869	22,869	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-67.1	-1,198,160	2,280,920	0.24%
May 15, 2024	MPM ASSET MANAGEMENT LLC	unchanged	-	4,372,150	8,777,630	3.58%

Are Funds Buying or Selling ADAP?

Are funds buying ADAP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADAP

No. of Funds

Unveiling Adaptimmune Therapeutics Plc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 02, 2024	new enterprise associates 14, l.p.	6.7%	102,478,672	SC 13D/A
Mar 26, 2024	ecor1 capital, llc	10.7%	164,424,420	SC 13G/A
Feb 14, 2024	long focus capital management, llc	5.3%	12,086,915	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	4.8%	65,815,692	SC 13G/A
Jan 30, 2024	ecor1 capital, llc	7.7%	113,424,420	SC 13G
Jan 29, 2024	baillie gifford & co	7.01%	95,472,840	SC 13G/A
Nov 08, 2023	long focus capital management, llc	2.9%	6,582,798	SC 13G
Jul 10, 2023	matrix capital management company, lp	17.29%	233,845,110	SC 13G/A
Mar 30, 2023	new enterprise associates 14, l.p.	10.3%	102,478,672	SC 13D/A
Feb 14, 2023	pfm health sciences, lp	3.0%	6	SC 13G/A

Recent SEC filings of Adaptimmune Therapeutics Plc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 15, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
Apr 22, 2024	ARS	ARS
Apr 12, 2024	8-K	Current Report
Apr 11, 2024	DEF 14A	DEF 14A
Apr 02, 2024	SC 13D/A	13D - Major Acquisition
Apr 01, 2024	PRE 14A	PRE 14A
Mar 26, 2024	3	Insider Trading

Peers (Alternatives to Adaptimmune Therapeutics Plc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Adaptimmune Therapeutics Plc News

Latest updates

Adaptimmune Therapeutics Plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	2358.0%	5,678,000	231,000	7,319,000	5,130,000	47,601,000	11,028,000	7,007,000	5,538,000	3,575,000	1,417,000	1,203,000	3,095,000	434,000	1,502,000	1,193,000	502,000	761,000	728,000	237,000	858,000	1,479,000
Costs and Expenses	9.7%	54,939,000	50,087,000	53,952,000	50,038,000	45,945,000	38,270,000	49,997,000	49,290,000	53,556,000	44,281,000	43,384,000	42,407,000	38,323,000	39,015,000	37,068,000	30,755,000	30,525,000	31,083,000	40,358,000	35,659,000	33,415,000
S&GA Expenses	-100.0%	-	16,879,000	16,164,000	20,073,000	20,397,000	15,218,000	16,815,000	14,550,000	16,804,000	14,776,000	15,173,000	13,539,000	13,817,000	13,238,000	13,001,000	10,295,000	9,261,000	10,729,000	10,741,000	10,148,000	10,816,000
R&D Expenses	6.0%	35,207,000	33,208,000	37,788,000	29,965,000	25,548,000	23,052,000	33,182,000	34,740,000	36,752,000	29,505,000	28,211,000	28,868,000	24,506,000	25,777,000	24,067,000	20,460,000	21,264,000	20,354,000	29,617,000	25,511,000	22,599,000
EBITDA Margin	-386.5%	-8.32	-1.71	-1.19	-1.16	-1.49	-5.81	-9.58	-14.41	-17.64	-24.67	-23.97	-22.90	-	-	-	-	-	-	-	-	-
Income Taxes	180.2%	526,000	-656,000	687,000	680,000	625,000	994,000	399,000	470,000	634,000	209,000	208,000	76,000	298,000	52,000	15,000	25,000	70,000	88,000	87,000	65,000	135,000
Earnings Before Taxes	1.2%	-47,977,000	-48,573,000	-44,914,000	-20,709,000	1,661,000	-28,256,000	-41,022,000	-44,050,000	-49,631,000	-38,649,000	-42,193,000	-38,992,000	-37,465,000	-36,561,000	-35,417,000	-29,855,000	-28,097,000	-29,276,000	-39,215,000	-41,022,000	-35,868,000
EBT Margin	-373.2%	-8.83	-1.87	-1.30	-1.25	-1.57	-6.00	-9.88	-14.87	-18.24	-25.58	-24.90	-23.85	-	-	-	-	-	-	-	-	-
Net Income	-1.2%	-48,503,000	-47,917,000	-45,601,000	-21,389,000	1,036,000	-29,250,000	-41,421,000	-44,520,000	-50,265,000	-38,858,000	-42,401,000	-39,068,000	-37,763,000	-36,613,000	-35,432,000	-29,880,000	-28,167,000	-29,364,000	-39,302,000	-41,087,000	-36,173,000
Net Income Margin	-371.2%	-8.90	-1.89	-1.34	-1.29	-1.60	-6.09	-9.98	-15.00	-18.36	-25.71	-25.00	-23.92	-	-	-	-	-	-	-	-	-
Free Cashflow	-106.7%	-32,052,000	-15,503,000	-45,448,000	-44,978,000	-39,632,000	-1,373,000	-58,166,000	-50,211,000	-61,515,000	129,912,000	-46,834,000	-33,231,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.7%	258	283	297	343	288	329	332	388	420	470	354	390	412	451	479	512	285	182	208	240	270
Current Assets	-9.9%	187	208	219	262	214	255	264	321	359	415	300	337	359	398	427	458	228	120	147	175	200
Cash Equivalents	-0.3%	144	144	90.00	77.00	120	108	81.00	100	91.00	152	45.00	55.00	37.00	61.00	83.00	127	91.00	55.00	44.00	39.00	54.00
Net PPE	-5.2%	48.00	51.00	53.00	55.00	54.00	54.00	48.00	45.00	37.00	30.00	29.00	29.00	28.00	28.00	27.00	27.00	29.00	31.00	32.00	34.00	36.00
Liabilities	-3.9%	234	243	209	216	204	247	219	246	257	264	113	112	102	110	103	105	99.00	58.00	61.00	53.00	51.00
Current Liabilities	-8.8%	66.00	73.00	75.00	76.00	64.00	65.00	66.00	74.00	66.00	63.00	41.00	41.00	31.00	39.00	35.00	39.00	30.00	34.00	37.00	28.00	23.00
Shareholder's Equity	-38.3%	24.00	40.00	88.00	127	84.00	82.00	113	142	163	206	241	278	309	341	376	408	186	124	148	187	220
Retained Earnings	-4.7%	-1,071	-1,023	-975	-929	-908	-909	-880	-838	-794	-743	-704	-662	-623	-585	-549	-513	-483	-455	-426	-387	-345
Additional Paid-In Capital	3.0%	1,097	1,065	1,061	1,058	993	991	985	980	965	960	955	950	942	936	933	929	678	586	583	581	578
Accumulated Depreciation	5.3%	48.00	46.00	43.00	41.00	39.00	39.00	35.00	36.00	37.00	36.00	35.00	34.00	33.00	31.00	29.00	26.00	24.00	24.00	21.00	20.00	18.00
Shares Outstanding	12.5%	1,533	1,363	1,362	1,352	994	987	981	963	940	935	934	934	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	191	-	-	-	244	-	-	-	584	-	-	-	1,360	-	-	-	349	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-117.7%	-31,950	-14,676	-45,159	-43,762	-37,283	2,042	-48,159	-41,251	-54,401	133,928	-45,200	-31,459	-46,540	-29,216	-16,317	-24,915	16,857	-12,528	-29,608	-34,168	-36,203
Share Based Compensation	0.7%	3,102	3,081	3,179	3,837	1,676	3,946	3,663	5,045	5,586	4,827	5,019	5,449	5,334	3,062	3,280	2,624	1,448	2,558	1,820	3,196	3,479
Cashflow From Investing	-100.5%	-358	68,197	57,306	2,694	48,341	20,952	28,851	44,109	-4,775	-28,491	34,851	47,678	21,762	7,608	-27,580	-187,005	-71,947	23,683	35,045	18,561	17,656
Cashflow From Financing	39406.8%	29,235	74.00	596	14.00	196	1,403	1,452	9,977	35.00	52.00	139	2,563	534	122	466	248,019	91,444	-	-	330	36.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADAP Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 5,678	$ 47,601
Operating expenses
Research and development	(35,207)	(25,548)
General and administrative	(19,732)	(20,397)
Total operating expenses	(54,939)	(45,945)
Operating (loss)/profit	(49,261)	1,656
Interest income	1,345	676
Other income (expense), net	(61)	(671)
(Loss)/profit before income tax expense	(47,977)	1,661
Income tax expense	(526)	(625)
Net (loss)/profit attributable to ordinary shareholders	$ (48,503)	$ 1,036
Net (loss)/profit attributable to ordinary shareholders
Basic (in dollars per share)	$ (0.03)	$ 0.00
Diluted (in dollars per share)	$ (0.03)	$ 0.00
Weighted average shares outstanding:
Basic (in shares)	1,451,241,661	991,330,402
Diluted (in shares)	1,451,241,661	1,000,276,615

ADAP Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 140,670,000	$ 143,991,000
Marketable securities - available-for-sale debt securities (amortized cost of $2,981 and $2,940) net of allowance for expected credit losses of $0 and $0	2,982,000	2,947,000
Accounts receivable, net of allowance for expected credit losses of $0 and $0	8,404,000	821,000
Other current assets and prepaid expenses	34,847,000	59,793,000
Total current assets	186,903,000	207,552,000
Restricted cash	2,858,000	3,026,000
Operating lease right-of-use assets, net of accumulated amortization of $14,381 and $13,220	19,434,000	20,762,000
Property, plant and equipment, net of accumulated depreciation of $48,445 and $46,020	48,291,000	50,946,000
Intangible assets, net of accumulated amortization of $5,198 and $5,155	524,000	330,000
Total assets	258,010,000	282,616,000
Current liabilities
Accounts payable	6,587,000	8,128,000
Operating lease liabilities, current	5,250,000	5,384,000
Accrued expenses and other current liabilities	23,050,000	30,303,000
Deferred revenue, current	31,524,000	28,973,000
Total current liabilities	66,411,000	72,788,000
Operating lease liabilities, non-current	18,442,000	19,851,000
Deferred revenue, non-current	147,365,000	149,060,000
Other liabilities, non-current	1,417,000	1,404,000
Total liabilities	233,635,000	243,103,000
Stockholders' equity
Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,532,974,878 issued and outstanding (2023: 1,702,760,280 authorized and 1,363,008,102 issued and outstanding)	2,081,000	1,865,000
Additional paid in capital	1,096,690,000	1,064,569,000
Accumulated other comprehensive loss	(2,720,000)	(3,748,000)
Accumulated deficit	(1,071,676,000)	(1,023,173,000)
Total stockholders' equity	24,375,000	39,513,000
Total liabilities and stockholders' equity	$ 258,010,000	$ 282,616,000

About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

CEO	Mr. Adrian G. Rawcliffe
WEBSITE	adaptimmune.com
INDUSTRY	Biotechnology
EMPLOYEES	534

Adaptimmune Therapeutics Plc Frequently Asked Questions

What is the ticker symbol for Adaptimmune Therapeutics Plc? What does ADAP stand for in stocks?

ADAP is the stock ticker symbol of Adaptimmune Therapeutics Plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adaptimmune Therapeutics Plc (ADAP)?

As of Fri May 17 2024, market cap of Adaptimmune Therapeutics Plc is 1.7 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADAP stock?

You can check ADAP's fair value in chart for subscribers.

What is the fair value of ADAP stock?

You can check ADAP's fair value in chart for subscribers. The fair value of Adaptimmune Therapeutics Plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adaptimmune Therapeutics Plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADAP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adaptimmune Therapeutics Plc a good stock to buy?

The fair value guage provides a quick view whether ADAP is over valued or under valued. Whether Adaptimmune Therapeutics Plc is cheap or expensive depends on the assumptions which impact Adaptimmune Therapeutics Plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADAP.

What is Adaptimmune Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ADAP's PE ratio (Price to Earnings) is -10.42 and Price to Sales (PS) ratio is 92.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADAP PE ratio will change depending on the future growth rate expectations of investors.